FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what FDA Peptide Category Update: Clarifying Misinformation Cole Thomas posted on the topic LinkedIn